PICASSIAS (8-04.3)
Approved for use through 07/13/2006 (6/04.0)

U.S. Peletra att (1/stekmaik Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of infamination unless of contains a value of the contains and unless of contains a value. Application Number

	Application (tullion		
INFORMATION DISCLOSURE	Filing Date		
	First Named Inventor Danie		iel GAGNON
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		
(Hot for Submission and or or it has)	Examiner Name		
	Attorney Docket Numb	er	PHUS030419US

	U.S.PATENTS							Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue [	Date	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Releva Figures Appear	
	1	4013485		1977-0	3-22	Ma, et al.		all	
	2	5457322		1995-1	0-10	Kitaguchi, et al.		all	
	3	6204087	B1	2001-0	3-20	Parker, et al.		all	
	4	6486476	B1	2002-1	1-26	Ochiai, et al.		all	
If you wish to add additional U.S. Patent citation information please click the Add button.						Add			
	U.S.PATENT APPLICATION PUBLICATIONS Remove								
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	ition	Name of Patentee or Applicant of cited Document		Releva	Columns,Lines where nt Passages or Relevant Appear
	1	20030035510	A1	2003-0	2-20	Strommer		all	
If you wis	If you wish to add additional U.S. Published Application citation information please click the Add button. Add								
FOREIGN PATENT DOCUMENTS Remove									
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Kind Code4	Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear

# Application Number Fing Date Fing Da

	1								
If you wis	If you wish to add additional Foreign Patent Document citation information please click the Add button Add								
NON-PATENT LITERATURE DOCUMENTS Remove									
Examine Initials*	Examiner Initials* Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, calatage, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						Ţδ		
	1 HAMILTON, W.J., et al.; Very High Resolution Detection of Gamma Radiation at Room-Temperature using P.I-N Detectors of CaZhiTe and HgCdTe; 1994, IEEE NSSMIC; 1:232-235.								
	2	OSINSKI, M., et al.; Effects of proton irradiation of AKGaN/InGaN/GaN/GaN green light emitting diodes, 1997; Electronics Letters; 33(14)1252-1253.							
If you wish to add additional non-patent literature document citation information please click the Add button Add									
EXAMINER SIGNATURE									
Examiner Signature Date Considered									

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kint Code of USPTO Patent Documents at year USPTO\_CODY or NEPP 691.04. 2 Enter office that issued the document, by the bondward set of the patent produced an immediate of the part of the Emperor must proced the sent number of the spart of the Component procedures are immediated to countered. Which code control of the year of the Emperor must procedure the sent number of the spart occurrent procedures are immediated countered. \*\*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST,16 if possible. \*\*Applicant is to place a check mark their of English stangages the relatation is distanced.\*\*

# Application Number Fing Date STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Application Number Fing Date First Number I PHIJS000419US

### CERTIFICATION STATEMENT

Please see 37 CFI	R 1 97 and 1 9	8 to make the a	annronniate sel	ection(s)

information disclosure statement. See 37 CFR 1.97(e)(1).

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the

# OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no tem of information contained in the information disclosure statement was known to any individual designated in 37 CFR 15(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement.

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- .7 None

### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Torri or the signature.			
Signature	/DBM/	Date (YYYY-MM-DD)	2006-04-18
Name/Print	Douglas B. McKnight	Registration Number	50447

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to life (and by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C. 12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. 0. Bot 1450, Alexandria, V.3.251.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.3.231.1450.

# Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.